Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
European Journal of Radiology|November 6, 2020
Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CTXingying Li, Xinli Xie, Lei Zhang, et al.
Annals of Hematology|June 14, 2014
Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patientsZhiyuan Zhou, Xiang Li, Changying Chen, et al.
Translational Oncology|November 30, 2025
Evaluation of the 1021-HRD assay compared to established HRD testing platforms in ovarian cancerEirini Papadopoulou, Elena Fountzilas, Vasiliki Metaxa-Mariatou, et al.
Frontiers in Oncology|July 5, 2021
Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment FailureJunxia Hu, Xin Wang, Fei Chen, et al.
Cancer Biology & Medicine|October 11, 2021
Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trialJingjing Wu, Fenghua Gao, Wenhua Wang, et al.
Oncotarget|July 8, 2016
Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149Lei Zhang, Sisi Jia, Yangyang Ma, et al.
Leukemia Research|June 10, 2022
DDGP followed by radiotherapy vs VIPD followed by radiotherapy in newly diagnosed early NK/T-cell lymphomaLei Zhang, Chenxing Shangguan, Xin Li, et al.
Therapeutic Advances in Medical Oncology|March 9, 2026
Fotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysisXudong Zhang, Wanyue Zhao, Wenhua Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2022
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/LymphomaMingzhi Zhang, Dan Chen, Xiaorui Fu, et al.
Nature Communications|September 19, 2019
Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphomaZhaoming Li, Xudong Zhang, Weili Xue, et al.
Pageof 10